Jean Siedel

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Combined VEGFR and MAPK pathway inhibition in angiosarcoma”.

Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Scientific Reports(2021)10.1038/s41598-021-88703-9

N/A

0.533DataRank · unranked

34 citations

Yasmin A. Lyons, Jean Siedel, Robert Dood, Archana S. Nagaraja, Monika Haemmerle +8 more

Post-operative gastroparesis following carbohydrate loading in a diabetic patient

Gynecologic Oncology Reports(2021)10.1016/j.gore.2021.100714

N/A

0DataRank · unranked

2 citations

Jean Siedel, Aaron Shafer, Jeffrey How

Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients

Gynecologic Oncology Reports(2024)10.1016/j.gore.2024.101498

N/A

0DataRank · unranked

1 citations

Kara J. Milliron, Jean Siedel, Shitanshu Uppal, Sofía D. Merajver, Karen McLean +1 more

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3877

N/A

0DataRank · unranked

8 citations

Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John +15 more

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.02.015

N/A

0DataRank · unranked

2 citations

Rebecca A. Previs, Daniel Spinosa, Bryan Fellman, Amelia L. Scott, Isabelle Mulder +10 more